Return to search

Hummingbird Bioscience extends Series B round

Hummingbird Bioscience, a biotherapeutics company, has extended its Series B funding to $25 million.

Hummingbird Bioscience, a biotherapeutics company, has extended its Series B funding to $25 million. The lead investor was SK Holdings, with participation from other backers that included Heritas Capital and SEEDS Capital, the investment arm of Enterprise Singapore.

Source: Press Release